The agreement covers drug substance and drug product manufacturing, with commercial production targeted to begin in 2027 at the CDMO’s Songdo facility.
The partnership will establish East Coast manufacturing capacity for the cell therapy and support a planned expansion of Made Scientific’s Princeton campus.
Three biopharma developers, including the Institute of Science Tokyo, selected the CDMO’s Yokohama site for cell therapy process development and manufacturing support.
The agreement gives the Hong Kong-based pharmaceutical company exclusive rights to use the TfR1 platform in up to two neurodegenerative disease programs.
The acquisition of the Chemistry, Manufacturing and Controls team adds more than 35 specialists in biologics development, production oversight, and regulatory strategy.